ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?

US FDA Approvals For Both Firms’ Antibodies Expected Early 2023

 
• By Mandy Jackson
  
Workers install new roofs using mobile cranes
Eisai's earlier analysis looked at lecanemab pricing as high as $38,053 • Source: Shutterstock

More from Drug Pricing

More from Scrip